Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Taiho’s DMD asset misses in phase 3 trial
Taiho's investigational DMD treatment has failed to impact the time it takes patients to rise from the floor, missing the phase 3 study’s main goal.
Gabrielle Masson
Jul 8, 2025 10:17am
ProKidney cell therapy wins half of trial, falls short on other
Jul 8, 2025 8:00am
Jasper warns of restructuring after dud drug derails trials
Jul 7, 2025 9:23am
Cogent hits primary endpoint, building case for Blueprint rival
Jul 7, 2025 9:16am
Apogee claims IL-13 antibody sets new eczema treatment standard
Jul 7, 2025 8:29am
Vyne prunes psoriasis trial, but keeps faith in BET inhibitor
Jul 2, 2025 10:33am